Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $7.7MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hohenleitner Susan | Officer | Aug 21 '26 | Proposed Sale | $4.03 | 2,650 | $10,680 | — | Aug 21 08:40 PM |
| Kelliher Mike | Officer | Aug 21 '26 | Proposed Sale | $4.03 | 10,500 | $42,315 | — | Aug 21 08:25 PM |
| Raab Michael | Officer | Aug 21 '26 | Proposed Sale | $4.03 | 44,500 | $179,335 | — | Aug 21 08:10 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.